About Lumora
Lumora is a company based in Ely (United Kingdom) founded in 2003 by Laurence Tisi was acquired by Erba Mannheim in September 2015. Lumora has raised $7.36 million across 3 funding rounds from investors including Tate & Lyle, University of Cambridge and Catapult Ventures. The company has 19 employees. Lumora offers products and services including Domain Auction Platform. Lumora operates in a competitive market with competitors including Prenetics, Inflammatix, Karius, Day Zero Diagnostics and MeMed, among others.
- Headquarter Ely, United Kingdom
- Employees 19
- Founders Laurence Tisi
- SectorsHealthcare
- Website lumora.co.uk
- Social LinkedIn
- Acquired by Erba Mannheim (Sep 2015)
- Legal Name Lumora Limited
- Date of Incorporation 22 Oct, 2002
- Jurisdiction ELY, CAMBRIDGESHIRE, ENGLAND
- Annual Revenue$2.38 M (USD)-9as on Dec 31, 2020
- Net Profit-$208.18 K (USD)-131as on Dec 31, 2020
- Total Equity Funding$7.36M (USD)
in 3 rounds
- Latest Funding Round$1.06M (USD), Series B
Mar 2013
- InvestorsTate & Lyle
& 3 more
- Employee Count19
- Acquired byErba Mannheim
(Sep 2015)
Products & Services of Lumora
Lumora offers a comprehensive portfolio of products and services, including Domain Auction Platform.
Platform for online bidding and purchasing of domain names.
Funding Insights of Lumora
Lumora has successfully raised a total of $7.36M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $1.06 million completed in March 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.36M
- Total Rounds 3
- Last Round Series B — $1.06M
- First Round $3.87M
(Jan 2007)
- Investors Count 3
All 3 funding rounds of Lumora with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2013 | $1.06M | Series B | – | Catapult Ventures, University of Cambridge | – |
| May 2011 | $2.43M | Series B | – | Catapult Ventures | |
| Jan 2007 | $3.87M | Series A | – | Tate & Lyle | – |
4 investors in total: 4 institutional.
Investors in Lumora
Lumora has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Tate & Lyle, University of Cambridge and Catapult Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment solutions are provided by Catapult Ventures for growth. | – | catapult-ventures.com | Leicester, United Kingdom | |
Multiple courses and degrees are offered across diversified academic streams. | 1209 | cam.ac.uk | Cambridge, United Kingdom | |
Manufacturer of food ingredients | 1921 | tateandlyle.com | London, United Kingdom | |
Erba provides diagnostic solutions for healthcare needs worldwide through research and development. | 1999 | erbamannheim.com | Mannheim, Germany |
Investor details for Lumora
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lumora
1 people are tracked at Lumora (1 in leadership); the tracked headcount is 19.
| Name | Role | Group |
|---|---|---|
Laurence Tisi | Co-Founder | Leadership |
Complete people profiles for Lumora
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Lumora
4 dated milestones of Lumora across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Lumora is founded.
- Funding First funding round of $3.9M.
- Funding Latest funding round, Series B, of $1.1M.
- Exit Acquired by Erba Mannheim.
Competitors of Lumora
Lumora operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Prenetics, Inflammatix, Karius, Day Zero Diagnostics and MeMed, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| dayzerodiagnostics.com | 2016 | Boston, United States | $48.6M | 48 | Genome sequencing diagnostics for infectious diseases are developed. | |
| me-med.com | 2009 | Tirat Carmel, Israel | $163M | – | Provider of machine learning based diagnostic solutions for infectious diseases | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. | |
| opgen.com | 2002 | Rockville, United States | $77.51M | 100 | Developer of diagnostics and bioinformatics platforms for providers | |
| clearlabs.com | 2014 | Menlo Park, United States | $171.09M | 55 | Food safety technologies are provided for pathogen identification. | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| sunbirdbio.com | 2020 | Singapore | $14M | – | Diagnostic technologies for infectious, cancer, and neurological diseases are developed. |
Detailed competitors of Lumora
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Lumora
10 companies that operate in the same segment as Lumora (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Lumora
Lumora was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Lumora is headquartered in Ely, United Kingdom. It is registered at Ely, Cambridgeshire, United Kingdom.
Lumora is a funded company, having raised a total of $7.36M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.87M, raised on Jan 2007.
Lumora has 19 employees.
Annual revenue of Lumora is $2.38M as on Dec 31, 2020.
Developer of molecular diagnostics for infectious diseases. The proprietary platform Bioluminescent Assay in Real-Time (BART) is a diagnostic reporter system that can be used in conjunction with isothermal PCR tests. Its flagship products are for diagnosing gastrointestinal infections and monitoring HIV viral loads.
Lumora's top competitors include Visby Medical, Inflammatix and Prenetics.
Lumora offers Domain Auction Platform.
Lumora has 4 investors. Key investors include Tate & Lyle, University of Cambridge, Catapult Ventures, and Erba Mannheim.
Lumora operates through Lumora Limited.
Yes. Lumora was acquired by Erba Mannheim in September 2015.